Price Target Increase Signals Investor Confidence
The average one-year price target for Arcutis Biotherapeutics (NasdaqGS:ARQT) has recently surged by 11.11% to 13.60 per share. This revision illustrates a sharp uptick from the former estimate of 12.24 back on January 16, 2024. Analysts have a mixed outlook, with price targets ranging from a low of 6.06 to a high of 21.00 per share. This adjustment averages to a 40.50% increase from the last reported closing price of 9.68 per share.
Fund Sentiment and Shareholders Activities
As of now, there are 295 funds or institutions disclosing their positions with Arcutis Biotherapeutics, reflecting a decrease of 35 owners or 10.61% in the last quarter. The mean portfolio weight of all funds assigned to ARQT is 0.06%, marking a decline of 24.25%. Notably, the total shares held by institutions have surged in the past three months by 46.98% to 110,504K shares, indicating growing institutional interest in the company.
Jennison Associates leads the pack with 9,066K shares, representing 9.61% ownership. The firm significantly bolstered its stake by 51.11% from the previous filing, boosting its portfolio allocation by 9.22% in ARQT over the last quarter. On the other hand, Frazier Life Sciences Management holds 8,764K shares, accounting for 9.29% ownership. Despite a minor increase of 0.91% in shares owned, the firm scaled back its portfolio allocation by 50.58% during the same period. Suvretta Capital Management and Rubric Capital Management made strategic moves by augmenting and diminshing their investments in ARQT, respectively.
In a similar vein, Polar Capital Holdings ramped up its stake, holding 6,298K shares, which translates to 6.67% ownership. The firm saw a remarkable 50.49% increase in shares owned, nudging its portfolio allocation up by 1.56% over the previous quarter.
Arcutis Biotherapeutics – Pioneering Immuno-Dermatology Solutions
Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, known as immuno-dermatology. Leveraging recent advancements in immunology and inflammation, the company is spearheading the creation of innovative therapies against biologically validated targets to address persistent treatment challenges in severe skin diseases.
The company’s robust pipeline consists of four novel drug candidates currently in development for various inflammatory dermatological conditions. Notable among them is the lead product candidate, topical roflumilast, poised to elevate the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.
Fintel stands out as one of the most comprehensive investing research platforms catering to individual investors, traders, financial advisors, and small hedge funds. Their data spans the globe and includes fundamentals, analyst reports, ownership data, fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and more. Furthermore, their exclusive stock picks are backed by advanced, backtested quantitative models to enhance profitability.
Discover more on Fintel to stay informed about the latest trends in the financial markets and make well-informed investment decisions.
This article originally appeared on Fintel.
The views and opinions expressed herein are the author’s own and do not necessarily reflect those of Nasdaq, Inc.
